Zekai Wu

Dr. Zekai Wu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
ZWZekai Wu
Zekai Wu
SLSihui Luo
Sihui Luo
XZXueying Zheng
Xueying Zheng
YBYan Bi
Yan Bi
WXWen Xu
Wen Xu
Jianping WengJianping Weng
Jianping Weng
Previous studies show that the use of do-it-yourself artificial pancreas system (DIYAPS) may be associated with better glycemic control characterized by improved estimated hemoglobin A1c (eHbA1c) and time in range among adults with type 1 diabetes (T1D). However, few studies have demonstrated the changes in laboratory-measured HbA1c, which is a more accepted index for glycemic control, after using a DIYAPS. This is a retrospective before-after study approaching patients who reported self-use of AndroidAPS. The main inclusion criteria included: T1D; aged ⩾18 years; having complete record of ⩾3 months of continuous AndroidAPS use; with laboratory-measured HbA1c and quality of life scale data before and after 3 months of AndroidAPS use; and not pregnant. The primary outcome was the change in HbA1c between baseline and 3 months after initiation of AndroidAPS use. Overall, 15 patients (10 females) were included; the median age was 32.2 years (range: 19.2–69.4), median diabetes duration was 9.7 years (range: 1.8–23.7) and median baseline HbA1c was 7.3% (range: 6.4–10.1). The 3 months of AndroidAPS use was associated with substantial reductions in HbA1c [6.79% (SD: 1.29) versus 7.63% (SD: 1.06), p = 0.002] and glycemic variability when compared with sensor-augmented pump therapy. A lower level of fear of hypoglycemia [22.13 points (SD: 6.87) versus 26.27 points (SD: 5.82), p = 0.010] was also observed after using AndroidAPS. The 3 months of AndroidAPS use was associated with significant improvements in glucose management and quality of life among adults with T1D.

28 May 2022 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
VMVirginie Messier
Virginie Messier
MTMeryem K. Talbo
Meryem K. Talbo
CGClaudia Gagnon
Claudia Gagnon
NTNadine Taleb
Nadine Taleb
RRRémi Rabasa-Lhoret
Rémi Rabasa-Lhoret

7 July 2023 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MTMeryem K Talbo
Meryem K Talbo
MLMaha Lebbar
Maha Lebbar
ZWZekai Wu
Zekai Wu
AVAndréane Vanasse
Andréane Vanasse
MLMarie-Laure Lalanne-Mistrih
Marie-Laure Lalanne-Mistrih
RRRemi Rabasa-Lhoret
Remi Rabasa-Lhoret

5 March 2022 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
KPKarine Paiement
Karine Paiement
VFValérie Frenette
Valérie Frenette
ZWZekai Wu
Zekai Wu
CSCorinne Suppère
Corinne Suppère
VMVirginie Messier
Virginie Messier
RRRémi Rabasa-Lhoret
Rémi Rabasa-Lhoret

31 January 2024 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
RMReid D. McClure
Reid D. McClure
MTMeryem K. Talbo
Meryem K. Talbo
ABAnne Bonhoure
Anne Bonhoure
JMJoséphine Molveau
Joséphine Molveau
CSCourtney A. South
Courtney A. South
ZWZekai Wu
Zekai Wu

24 December 2020 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
DYDaizhi Yang
Daizhi Yang
JYJinhua Yan
Jinhua Yan
HDHongrong Deng
Hongrong Deng
XYXubin Yang
Xubin Yang
SLSihui Luo
Sihui Luo
WXWen Xu
Wen Xu
Background. To comprehensively assess the effects of metformin added to insulin on metabolic control, insulin sensitivity, and cardiovascular autonomic function in adolescents with type 1 diabetes. Materials and Methods. This was an exploratory, crossover, randomized trial conducted in adolescents with type 1 diabetes aged 12-18 years old. Participants were randomly received metformin (≤1000 mg/d) added to insulin for 24 weeks followed by insulin monotherapy for a subsequent 24 weeks or vice versa. Blood pressure, body mass index, insulin dose, estimated insulin sensitivity, glycated hemoglobin A1c (HbA1c), and lipid profiles were measured, with a 72-hour continuous glucose monitoring and 24-hour Holter monitoring performed at baseline, 24, and 50 weeks for the assessments of glucose variability and heart rate variability. Results. Seventeen patients with age , body mass index , median (IQR) diabetes duration 4.50 (3.58, 6.92) years, and HbA1c 9.0% (8.5%, 9.4%) were enrolled. The between-group difference in HbA1c of 0.28% (95% CI -0.39 to 0.95%) was not significant ( ). Changes in body mass index, insulin dose, blood pressure, lipid profiles, and estimated insulin sensitivity were similar for metformin add-on vs. insulin monotherapy. Glucose variability also did not differ. Compared with insulin monotherapy, metformin add-on significantly increased multiple heart rate variability parameters. Conclusions. Metformin added to insulin did not improve metabolic control or glucose variability in lean/normal-weight adolescents with type 1 diabetes. However, metformin added to insulin significantly increased heart rate variability, suggesting that metformin might improve cardiovascular autonomic function in this population.